NCT04348916 - Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions

CancerMelanomaSolid TumorSquamous Cell Carcinoma of Head and NeckBreast CancerAdvanced Solid TumorTriple Negative Breast CancerColorectal CarcinomaNon-melanoma Skin CancerLiver Metastases

Interventions

BIOLOGICAL

ONCR-177

Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1

BIOLOGICAL

pembrolizumab

Anti-PD-1 monoclonal antibody

Trial Locations (11)

14263

Roswell Park Cancer Institute, Buffalo

30322

Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute - Tennessee Oncology, Nashville

43210

The Ohio State University Wexner Medical Center James Cancer Hospital, Columbus

78701

The University of Texas at Austin, Austin

80218

Sarah Cannon Research Institute at HealthONE, Denver

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

M5G 2M9

University Health Network, Princess Margaret Cancer Centre, Toronto